Latest News-I-Mab Mediaroom_Page

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

GAITHERSBURG, Md. and SHANGHAI, Aug. 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2022-08-23 21:13 3287

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

- Major updates will focus on global clinical development of core assets, upcoming milestones and ...

2022-08-19 21:00 2209

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-07-18 20:00 1782

I-Mab to Host 2022 R&D Day

GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasd...

2022-07-06 20:00 1604

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2022-06-23 20:00 1586

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-06-15 22:37 2607

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2022-05-31 20:00 1688

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

- Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with tori...

2022-05-27 05:01 2201

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB),...

2022-05-19 20:00 1828

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasda...

2022-05-05 20:00 1622

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, glo...

2022-04-29 04:01 1663

I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment

SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2022-03-31 20:00 1296

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021

* Financial results demonstrate strong fundamentals * Twenty key clinical milestones achieved ye...

2022-03-29 18:10 2686

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-03-18 20:00 3539

I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., March 15, 2022 /PRNewswire/ -- I-Mab ( "I-Mab" or the "Company") (N...

2022-03-15 20:00 1602

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-03-09 21:00 1712

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-03-03 21:00 1835

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-01-28 21:00 2482

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2022-01-18 21:00 1517

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

* The execution demonstrates senior management team's tremendous confidence in the Company's inno...

2022-01-14 21:00 6607